Literature DB >> 25504915

Factors affecting time to maintenance dose in patients initiating warfarin.

Brian S Finkelman1, Benjamin French, Luanne Bershaw, Stephen E Kimmel.   

Abstract

PURPOSE: Patients starting warfarin often experience lengthy dose-titration periods, when they are at high risk for bleeding and thromboembolism. However, relatively little is known about why some patients take longer than others to reach maintenance dose. Thus, we sought to identify social, clinical, and genetic factors associated with prolonged time to maintenance dose (TTM).
METHODS: We conducted a time-to-event analysis, using a prospective cohort of patients initiating warfarin (N = 390). Additionally, we examined whether changes in post-initiation factors were associated with TTM. Finally, we performed a secondary analysis in a subcohort (N = 156) assessing the effect of adherence on TTM.
RESULTS: No genetic or post-initiation factors were significantly associated with TTM. However, previous use of warfarin [hazard ratio (HR) = 0.64; 95% confidence interval (CI) 0.46, 0.88], current smoking status (HR = 0.61; 95%CI 0.39, 0.96), fewer than four doctor's visits in the previous year (HR = 0.63 vs 4-12 visits; 95%CI 0.46, 0.88), and worse general health status (HR = 0.63; 95%CI 0.47, 0.84) were significantly associated with longer TTM. Use of illegal injectable drugs (HR = 2.51; 95%CI 1.17, 5.39) was associated with shorter TTM. On secondary analysis, the HR for better adherence and TTM was 1.70 (95%CI 0.88, 3.27).
CONCLUSIONS: Time to maintenance dose was associated with pre-existing behavioral factors, health care utilization, and health quality but not clinical comorbidities or genetic factors in patients initiating warfarin. Future studies are needed to determine whether warfarin patients with prolonged TTM would have better outcomes on alternative agents.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  pharmacoepidemiology; pharmacogenetics; race; survival analysis; treatment effectiveness; warfarin

Mesh:

Substances:

Year:  2014        PMID: 25504915      PMCID: PMC4570031          DOI: 10.1002/pds.3735

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  37 in total

1.  Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.

Authors:  Nita A Limdi; Donna K Arnett; Joyce A Goldstein; T Mark Beasley; Gerald McGwin; Brian K Adler; Ronald T Acton
Journal:  Pharmacogenomics       Date:  2008-05       Impact factor: 2.533

2.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).

Authors:  Brian F Gage; Yan Yan; Paul E Milligan; Amy D Waterman; Robert Culverhouse; Michael W Rich; Martha J Radford
Journal:  Am Heart J       Date:  2006-03       Impact factor: 4.749

3.  Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians.

Authors:  H Schelleman; Z Chen; C Kealey; A S Whitehead; J Christie; M Price; C M Brensinger; C W Newcomb; C F Thorn; F F Samaha; S E Kimmel
Journal:  Clin Pharmacol Ther       Date:  2007-02-28       Impact factor: 6.875

4.  Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans.

Authors:  S E Kimmel; J Christie; C Kealey; Z Chen; M Price; C F Thorn; C M Brensinger; C W Newcomb; A S Whitehead
Journal:  Pharmacogenomics J       Date:  2007-02-27       Impact factor: 3.550

5.  Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity.

Authors:  Carmel Kealey; Zhen Chen; Jason Christie; Caroline F Thorn; Alexander S Whitehead; Maureen Price; Frederick F Samaha; Stephen E Kimmel
Journal:  Pharmacogenomics       Date:  2007-03       Impact factor: 2.533

6.  The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study.

Authors:  Stephen E Kimmel; Zhen Chen; Maureen Price; Catherine S Parker; Joshua P Metlay; Jason D Christie; Colleen M Brensinger; Craig W Newcomb; Frederick F Samaha; Robert Gross
Journal:  Arch Intern Med       Date:  2007-02-12

7.  Development of a contemporary bleeding risk model for elderly warfarin recipients.

Authors:  Theresa I Shireman; Jonathan D Mahnken; Patricia A Howard; Timothy F Kresowik; Qingjiang Hou; Edward F Ellerbeck
Journal:  Chest       Date:  2006-11       Impact factor: 9.410

8.  An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.

Authors:  Lisa M Meckley; Ann K Wittkowsky; Mark J Rieder; Allan E Rettie; David L Veenstra
Journal:  Thromb Haemost       Date:  2008-08       Impact factor: 5.249

9.  Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study.

Authors:  Catherine S Parker; Zhen Chen; Maureen Price; Robert Gross; Joshua P Metlay; Jason D Christie; Colleen M Brensinger; Craig W Newcomb; Frederick F Samaha; Stephen E Kimmel
Journal:  J Gen Intern Med       Date:  2007-06-22       Impact factor: 5.128

10.  Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.

Authors:  B F Gage; C Eby; J A Johnson; E Deych; M J Rieder; P M Ridker; P E Milligan; G Grice; P Lenzini; A E Rettie; C L Aquilante; L Grosso; S Marsh; T Langaee; L E Farnett; D Voora; D L Veenstra; R J Glynn; A Barrett; H L McLeod
Journal:  Clin Pharmacol Ther       Date:  2008-02-27       Impact factor: 6.875

View more
  3 in total

1.  Predicting prolonged dose titration in patients starting warfarin.

Authors:  Brian S Finkelman; Benjamin French; Luanne Bershaw; Colleen M Brensinger; Michael B Streiff; Andrew E Epstein; Stephen E Kimmel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-07-26       Impact factor: 2.890

2.  Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine.

Authors:  Basim Mohammad Ayesh; Ahmed Shaker Abu Shaaban; Abdalla Asaf Abed
Journal:  Future Sci OA       Date:  2018-01-10

3.  Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study.

Authors:  Géric Maura; Antoine Pariente; François Alla; Cécile Billionnet
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-07-28       Impact factor: 2.890

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.